Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951735 | 0.88 | ALOX5 (0.51) | ABCB1HTR1ADRD2MAOBL3MBTL1 | |
| SCHEMBL3211308 | 0.87 | CYP4F2 (0.49) | ABCB1HTR1ADRD2MAOBL3MBTL1 | |
| SCHEMBL3217103 | 0.85 | LTA4H (0.50) | ABCB1HTR1ADRD2L3MBTL1MTNR1B | |
| SCHEMBL3208113 | 0.81 | KDM4E (0.44) | ABCB1HTR1ADRD2MAOBL3MBTL1 | |
| SCHEMBL3218781 | 0.79 | L3MBTL1 (0.47) | L3MBTL1FFAR1 | |
| SCHEMBL19068931 | 0.78 | MAOB (0.51) | HTR1AMAOBL3MBTL1ALOX5KDM4E | |
| SCHEMBL3217506 | 0.77 | CNR1 (0.39) | HTR1AFFAR1 | |
| SCHEMBL3206631 | 0.76 | POLB (0.44) | — | |
| SCHEMBL10469385 | 0.76 | RAB9A (0.49) | ABCB1HTR1ADRD2MAOBL3MBTL1 | |
| SCHEMBL9430298 | 0.76 | MAOB (0.45) | ABCB1HTR1AMAOBL3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | ABCB1 1127/4885HTR1A 4068/4885DRD2 4826/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | ABCB1 868/4885HTR1A 4007/4885DRD2 4745/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | ABCB1 1127/4885HTR1A 4068/4885DRD2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.